Explore this article's sources with AI
Follow PeptideMethods on Google
LEAP-BED Semaglutide and Tirzepatide Pilot
A 41-person prospective pilot found an early symptom signal, but its small nonrandomized comparison cannot establish treatment efficacy.
Why we wrote this. A small prospective pilot can be mistaken for randomized efficacy evidence. This readout keeps the signal within its design limits.
In this article (4 sections)
LEAP-BED was a prospective pilot study of adults with binge eating disorder and overweight or obesity. It followed 29 people who received psychological support plus semaglutide or tirzepatide and 12 who received psychological support alone[1]. The study can show whether outcomes changed in these small groups. It cannot provide randomized proof that adding either medicine caused the change.
The paper is titled Semaglutide or Tirzepatide Added to Psychological Support in Binge Eating Disorder With Overweight or Obesity. PubMed lists it as a 2026 journal article in Diabetes, Obesity and Metabolism, with DOI 10.1111/dom.71510[2]. The title matters here: this was a pilot of medication added to psychological support, not a comparison of medication against no care.
What LEAP-BED measured
The reported supporting figure tracks Binge Eating Scale scores from baseline to follow-up. It shows individual trajectories and group means for the medication-plus-support group and the support-alone group. The scale is a symptom measure. A change in score is not the same as a blinded diagnosis, durable remission, or evidence that a medicine should be prescribed for binge eating disorder.
The researchers defined response before the analysis as either a follow-up Binge Eating Scale score below 17 or a reduction of at least 50% from baseline. That combined definition allows two paths to the same endpoint. A participant could cross the score threshold without a 50% reduction, or achieve a large relative reduction while remaining at or above 17[1]. Readers therefore need the actual score trajectories alongside the response label.
The figure also presents percentage changes in anthropometric, behavioral, and metabolic measures. The accessible record does not provide enough numerical detail to turn those secondary measures into separate efficacy claims. This readout does not infer unreported effect sizes, follow-up duration, doses, or adverse-event rates.
The response comparison was borderline
The difference in response between the combined anti-obesity-medication group and the psychological-support control group had a Fisher exact p value of 0.052[1]. That sits just above the conventional 0.05 threshold, but the more important issue is precision. With 29 participants in one group and 12 in the other, a small change in who meets the response definition can materially shift the result.
A p value does not measure the size or clinical importance of a difference. It also does not correct a nonrandomized comparison for baseline differences, treatment selection, or follow-up patterns. The pilot may identify a signal worth testing. It cannot establish that medication added to psychological support is effective for binge eating disorder.
The control group is useful because symptoms can change during psychological support and follow-up. Yet the groups may not have started with the same prognosis. Medicine choice may have reflected weight, metabolic health, prior treatment, preference, access, or clinician judgment. A small pilot cannot reliably balance all of those factors without randomized allocation.
Semaglutide and tirzepatide were not compared head to head
The study included both semaglutide and tirzepatide. The reported comparison between their response rates was not statistically significant, with a Fisher exact p value of 0.63[1]. That result does not show equivalence. Small subgroups can miss meaningful differences because estimates are imprecise.
The medicines also do not have identical pharmacology. Semaglutide is a GLP-1 receptor agonist, while tirzepatide acts at GIP and GLP-1 receptors. Pooling them may be reasonable for an early feasibility signal, but the combined result cannot reveal whether one drug drove the pattern or whether either had a medicine-specific effect on binge eating symptoms.
Weight change and eating-disorder symptoms must remain separate outcomes. A person can lose weight without achieving a clinically meaningful improvement in binge eating, and symptom scores can improve without a large weight change. The pilot title and supporting figure do not justify treating weight loss as proof that binge eating disorder improved.
What this pilot can and cannot tell us
The study is useful as prospective early evidence. It followed a defined clinical group, retained psychological support in both arms, and displayed individual symptom trajectories rather than only a pooled average. Those choices help readers see variation that a single mean can hide.
Its limits are substantial. The total sample was 41, the support-alone group contained 12 people, and the medicine group combined two treatments. The accessible materials do not report randomized allocation, blinding, a prespecified primary effect estimate with confidence interval, or enough harms detail for a safety comparison. No causal or comparative treatment conclusion should be built from this design.
The next test should randomly assign enough participants to medication plus defined psychological care or the same psychological care alone. It should prespecify binge frequency and validated symptom outcomes, report retention and missing data, and follow participants long enough to assess durability. Medicine-specific estimates and adverse events should be reported separately.
For now, LEAP-BED supports a research question rather than a treatment recommendation. The observed symptom pattern may justify a larger controlled trial. It does not establish semaglutide or tirzepatide as a treatment for binge eating disorder, and it does not tell clinicians or patients which medicine would be preferable.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Was LEAP-BED a randomized clinical trial?
No randomized allocation is reported in the accessible materials. It was a prospective pilot with 29 participants receiving medication plus psychological support and 12 receiving psychological support alone.
Did the pilot prove semaglutide or tirzepatide treats binge eating disorder?
No. The small study found an early symptom signal, but its design cannot establish that either medicine caused the observed changes or is an effective treatment for binge eating disorder.
Did tirzepatide work better than semaglutide?
The subgroup response comparison was not statistically significant, but the small sample cannot establish that the medicines are equivalent or reliably rank them.
Sources
No revisions yet. First published .